Clinical Takeaway
In this randomized, double-blind, placebo-controlled trial of patients with fibromyalgia, CBD did not demonstrate superiority over placebo in reducing pain. These findings highlight the gap between widespread patient use of CBD for fibromyalgia and the current clinical evidence supporting that practice. Clinicians should communicate these results clearly to patients while continuing to evaluate emerging data.
#7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Citation: Rasmussen Marianne Uggen et al.. Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.. Annals of the rheumatic diseases. 2026. PMID: 40846590.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This randomized controlled trial provides rigorous evidence evaluating CBD’s analgesic efficacy in fibromyalgia, a condition where current treatment options are limited and often inadequately effective. The double-blind, placebo-controlled design addresses a significant gap in the literature, as CBD is widely used by fibromyalgia patients despite insufficient clinical validation of its benefit. These findings could inform evidence-based prescribing practices and guide patients and clinicians in treatment selection for this difficult-to-manage chronic pain condition.
Quality Gate Alerts:
- Preclinical only
Abstract: OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.
💊 This Danish randomized controlled trial provides methodologically sound evidence that cannabidiol alone does not demonstrate superiority over placebo for fibromyalgia pain reduction, which is important given the widespread off-label use of CBD in this population. The single-center design and likely modest sample size warrant caution in generalizing findings, and the trial does not address potential synergistic effects of CBD combined with other cannabinoids or adjunctive therapies commonly used in clinical practice. Additionally, fibromyalgia’s heterogeneous presentation and high placebo response rates may have obscured benefit in specific patient subgroups not analyzed in this study. For clinicians considering CBD recommendations, this evidence suggests that isolated CBD is unlikely to be an effective monotherapy for fibromyalgia pain, supporting instead a more conservative approach that prioritizes established multimodal interventions including physical therapy, cognitive behavioral therapy, and guideline-approved pharmacotherapy while reserving cannabis-derived products for carefully selected patients who have exhausted conventional options and prefer botanical medicines.